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osting by EAbstract Primary cutaneous aggressive CD8+ T-cell lymphoma is an extremely rare entity with
distinct clinicopathological features. We report a case of a 28-year-old man that clinically presented
with an ulcerated nodule on his trunk and extremities. Histopathologic sections showed an ulcer-
ated epidermis with a diffuse lymphocytic inﬁltrate in the superﬁcial dermis with focal epidermot-
ropism. Immunohistochemically, the tumor cells were positive for CD3 and CD8 but negative for
CD4, CD20, CD30 and CD56. Granzyme B was positif. He received UVB therapy subsequently
associated to interferon with an important regression of the nodules.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Primary cutaneous lymphomas are deﬁned as a clonal accumu-
lation of lymphocytes originating in the skin, without extracu-
taneous manifestations after presentation and at 6 months
thereafter. It is believed that lymphocyte cell adhesion recep-
tors are involved in the tissue-speciﬁc dissemination of speciﬁc
subtypes of lymphoma. Selectin, integrin, immunoglobulin,
and CD44 isoforms comprise a group of distinct homing
receptors that exhibit selective lymphocyte binding properties.4144955.
.B. Dhaou).
y. Production and hosting by
Saud University.
lsevierAmong these receptors, CD44 expression is most likely related
to lymphoma dissemination and thus may be a contributor to
tumor aggressiveness. Numerous studies have shown that pri-
mary cutaneous Cutaneous T-cell lymphoma is an heteroge-
neous group of clonal lymphoproliferative disorders. There
are ﬁve entities: Se´zary syndrome, primary cutaneous Natural
Killer (NK)/T-cell lymphoma nasal type, primary cutaneous
aggressive CD8+ T-cell lymphoma, primary cutaneous T-cell
lymphoma and primary cutaneous peripheral T-cell lymphoma
unspeciﬁed. We report a rare case of primary cutaneous lym-
phoma type primary cutaneous aggressive CD8+ T-cell
lymphoma.
2. Case report
A 28-year-old man with no medical history was referred to our
department for fever and cutaneous eruption of limbs. He re-
ported a 2 week history of fever with gradually extending nod-
ular lesion from limbs to chest. Physical examination showed a
temperature at 40, pruritic and scattered, non-ulcerated pap-
ules and nodules on his trunk and extremities (Photos. 1–3).
The nodules diameter ranged from 1 to 4 cm. Bilateral
Figure 1 Dense lymphoid cells inﬁltrating dermis and subcutis.
Photo 1 Ulcerative lesion on the trunk.
Photo 2 Papular lesion on extremities.
Photo 3 Papular lesion on extremities.
Figure 2 Immunohistochemical stains shows diffuse positive
CD8 cells.
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were also observed. There was no lymphadenopathy nor
organomegaly.
Laboratory tests showed a normal complete blood cell
count with haemoglobin at 15.8 g/dl, platelet at 224 · 109/L,
leucocyt at 4.9 · 109/L (neutrophils: 55%, lymphocytes: 31%,
monocytes: 13%), C reactive-protein at 7 mg/l (normal range
<10 mg/l), an elevated serum levels of transaminases with
aspartate aminotransferase at 54 IU/L (normal range <45),
alanine aminotransferase at 46 IU/L (normal range <45),and elevated gamma-glutamyl transferase at 98 UI/L (normal
range 4–50).
To establish the diagnosis, an incisional biopsy of one of the
nodules was performed. Microscopic examination revealed a
dense and diffuse inﬁltrate of small to medium sized lymphoid
cells through out all layers of the dermis and subcutaneous
(Fig. 1). On immunohistochemical test, the tumor cells were po-
sitive for CD3, CD8 (Fig. 2) and the Granzyme B but negative
for CD4, CD20, CD30 and CD56. The histological diagnosis
was a cutaneous CD8+ T lymphoma.
Serological tests for human immunodeﬁciency virus (HIV)
and human man T-lymphotropic virus (HTLV) type 1 and 2
were negative. Screening for hepatitis B and C was positive
without viremia or replication on PCR test. The rest of infec-
tion disease including Epstein–Barr virus (EBV), toxoplasma,
rubeola, syphilis, brucellosis, tuberculosis and Ricketssiosis
was all negative. Anti-nuclear antibody, Antineutrophil cyto-
plasmic antibodies (ANCA) and cryoglobulinemia were nega-
tive. Bone marrow biopsy, chest X-ray and computed
tomography scans of the neck, chest and abdomen were all
normal.
The diagnosis of primary cutaneous lymphoma type pri-
mary cutaneous aggressive CD8+ T-cell lymphoma was then
made. He received UVB therapy subsequently associated to
interferon with an important regression of the nodules.
Table 1 International society for cutaneous lymphomas/European organization of research and treatment of cancer revisions to the
classiﬁcation and staging of mycosis fungoides/Se´zary syndrome.a
TNMB stages Description of TNMB
Skin
T1 Limited patches, papules, and/or plaques covering <10% of the skin surface; may further stratify into T1a (patch only) vs. T1b
(plaque ± patch)
T2 Patches, papules, or plaques covering P10% of the skin surface; may further stratify into T2a (patch only) vs. T2b
(plaque ± patch)
T3 One or more tumors (P1 cm diameter)
T4 Conﬂuence of erythema covering P80% body surface area
Node
N0 No clinically abnormal peripheral lymph nodes; biopsy not required
N1 Clinically abnormal peripheral lymph nodes; histopathology Dutch Gr 1 or NCI UV0–2
N1a Clone-negative
Nlb Clone-positive
N2 Clinically abnormal peripheral lymph nodes; histopathology Dutch Gr 2 or NCI LN3
N2a Clone-negative
N2b Clone-positive
N3 Clinically abnormal peripheral lymph nodes; histopathology Dutch Gr 3–4 or NCI LN4; clone-positive or -negative
Nx Clinically abnormal peripheral lymph nodes, no histologic conﬁrmation
Visceral
Mo No visceral organ involvement
M1 Visceral involvement (must have pathology conﬁrmation and organ involved should be speciﬁed)
Blood
B0 Absence of signiﬁcant blood involvement 65% of peripheral blood lymphocytes are atypical (Se´zary) cells
B0a Clone-negative
B0b Clone-positive
Bl Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Se´zary) cells but does not meet the criteria of B2
B1a Clone-negative
B1b Clone-positive
B2 High blood tumor burden: P1000/uL Se´zary cells with positive clone; one of the following can be substituted for Se´zary cells:
CD4/CD8P 10, CD4+ CD7 cells P40%, or CD4+ CD26 cells P30%
TNMB, Tumor, node, metastasis, blood (classiﬁcation).
a This research was originally published in Blood. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the
staging and classiﬁcation of mycosis, fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas
(ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EOHTC). Blood
2007;110:1713–1722. ª American Society of Hematology.
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Cutaneous lymphomas represent a substantial diagnostic and
therapeutic challenge due to their widespread clinical presenta-
tions and the numerous available therapeutic modalities which
require multi-disciplinary collaboration and expertise. Primary
cutaneous lymphomas are rare with an estimated annual inci-
dence of 1/100,000 (Smith and Wilson, 2008). As a group, they
have a heterogeneous clinical behavior. Different types of cuta-
neous B-cell lymphomas (CBCLs) and cutaneous T-cell lym-
phomas (CTCLs) can be distinguished. CTCLs are much
more common and represent approximately 75% of all pri-
mary cutaneous lymphomas (Bachelez, 2007).
Different types of primary cutaneous lymphoma are in-
cluded in the new World Health Organization–European
Organization Research and Treatment of Cancer (EORTC)
(Table 1) (Bachelez, 2007; Berti et al., 1999; Heald et al.,
2008; Masahiro et al., 2009).
Cutaneous T-cell lymphomas are a group of diseases uni-
ﬁed by several features including: the proliferation of skin
homing T-cells in the skin, the monoclonal nature of these
T-cells and the potential of almost all forms of CTCL to trans-form into high grade T-cell lymphoma (Drillenburg and Pals,
2000; Michel et al., 2003).
Cytotoxic cutaneous lymphomas are uncommon and usu-
ally express a CD8 and/or CD56 positive phenotype (Berti
et al., 1999; Burg et al., 2005) They represent a heterogeneous
group of lymphomas. All cytotoxic lymphocytes express a set
of toxic proteins, e.g. perforins, granzymes A (GrA), B
(GrB), and the T-cell intracellular antigen-1 (TIA-1), which
are reliable markers of cells with activated cytotoxic function
(Drillenburg and Pals, 2000).
CTCL expressing a CD8+ T-cell phenotype is extremely
rare (Burg et al., 2005); we found 6 cases of CD30+ CD8+
CTCL in the literature. Among these, 4 were Anaplastic large
cell lymphomas (ALCLs) and the others were borderline cases
considered as ALCLs with histological features of lymphoma-
toid papulosis. Three cases of ALCL showed a good clinical
outcome (free of disease for 2 years, 30 months and 55 months,
respectively) (Burg et al., 2005). It is suggested that CD8+
expression alone cannot be a hallmark for a poor prognosis.
The increase in all types of lymphoma over the last several
decades has led to research into other causes, including envi-
ronmental exposures. In certain geographic areas, a virus, ﬁrst
28 Z. Aydi et al.isolated from the cells of a patient with cutaneous lymphoma,
appears to be the cause of some lymphomas. However, this
relationship is not evident in most patients (Berti et al., 1999;
Burg et al., 2005). EBV is highly associated with peripheral
T-cell lymphoma, especially among patients in the Asian
region.
Because of the small number and the heterogeneity in clin-
ical presentation and course of the published cases, CD8+
CTCL were not included as a separate group in the EORTC
classiﬁcation for primary cutaneous lymphomas.
Treatment for CTCL depends on the type and stage of the
disease (Bachelez, 2007; Neelis et al., 2009). Treatment options
include phototherapy, radiation, topical therapy, systemic sin-
gle-agent chemotherapy, combination chemotherapy and com-
bined therapies. Patients in the early phase of disease have the
best response to treatment (Smith and Wilson, 2008). Patients
with localized early-stage disease are usually treated with top-
ical agents such as nitrogen mustard (Mustargen), skin-soft-
ening agents, anti-itch agents and gradual exposure to sunlight
or ultraviolet light (Kuzel et al., 2003). It is applied daily either
to affected areas of skin or to all skin surfaces. Patients, after
taking Psoralen which is a drug that binds to the DNA in
malignant cells, are then exposed to ultraviolet light. This is
activating the drug, which damages the malignant cell DNA.
Low-dose alpha-interferon, combined with Psoralen and ultra-
violet light (PUVA) therapy, has shown promising preliminary
results for patients with early-stage disease (Kuzel et al., 2003).
Narrow-band UVB, a form of phototherapy, is also used to
treat patch-stage cutaneous lymphoma.
Electron beam radiation conventional radiation therapy
penetrates the skin and reaches areas inside the body (Heald
et al., 2008; Neelis et al., 2009). Treatment leads to complete
clearing of lesions in several months without further treatment.
Some patients appear to have longstanding regression of their
skin lesions following this type of treatment.
Chemotherapy Several combinations of chemotherapeutic
agents have been used in patients with skin lymphoma, espe-
cially those with disease that involves the lymph nodes or other
organs, or those with Se´zary syndrome (Ginette and Peter,
2009).
Effective therapies include methotrexate, gemcitabine and
liposomal anthracyclines. Other agents such as etoposide
(VP-16), cyclophosphamide and pentostatin may also be used.
Bexarotene (Targretin), which is a retinoid derived from a
form of Vitamin A, may be used in early-stage or refractory
cutaneous lymphomas and combined with other therapies.
Bexarotene has been studied in patients with both advanced
and early-stage cutaneous T-cell lymphoma. A topical gel form
of bexarotene may play a role in treating localized lesions
(Martin, 2003).
Denileukin diftitox (Ontak), wich is a type of drug called
a ‘‘fusion protein’’, attaches to the cell surface of T cutaneous
lymphocytes. Studies have shown that patients with advanced
or recurrent CTCL who responded to denileukin diftitox treat-
ment also experienced signiﬁcant improvements in their qual-ity of life, severe itching and skin appearance (Duvic et al.,
2002).
Vorinostat (Zolinza)(Martin, 2003) is also approved to
treat CTCL in patients who have progressive, persistent or
recurrent disease during or after treatment with two systemic
therapies. This drug is a type of drug called a ‘‘histone deace-
tylase inhibitor.’’ Other histone deacetylase inhibitor drugs are
being studied for their effectiveness in treating CTCL.
4. Conclusion
Cutaneous lymphomas represent a substantial diagnostic and
therapeutic challenge due to their widespread clinical presenta-
tions and the numerous available therapeutic modalities which
require multi-disciplinary collaboration and expertise.
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